Gilead Sciences Inc (GILDm)

Buenos Aires
Currency in ARS
31,900.000
-775.000(-2.37%)
Closed·

BCBA:GILDm Financials

Key Ratios

P/E Ratio22.62
Price/Book6.66
Debt / Equity130.79%
Return on Equity32.66%
Dividend Yield2.94%
EBITDA13.45B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa24,68927,30527,28127,11628,754
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa20,99821,77921,62421,09722,503
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa10,95911,93210,9749,27710,687
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa1236,2254,5925,665480
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa68,40767,95263,17162,12558,995
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa11,39711,61011,23711,28012,004
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa18,22121,06421,20922,74919,246
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa7,965.3810,202.886,935.388,465.1310,130.75
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa8,16811,3849,0728,00610,828
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-14,615-3,131-2,466-2,265-3,449
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa770-8,877-6,469-5,125-3,433
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-5,634-659746733,906
* In Millions of USD (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.78%
Dividend Yield
2.87%
Industry Median 1.17%
Annualized Payout
938.44
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 07, 2025
EPS / Forecast
1.04 / --
Revenue / Forecast
6.67B / --
EPS Revisions
Last 90 days

FAQ

What were Gilead Sciences's earnings for the latest quarter?

The Gilead Sciences EPS (TTM) is 4.78. Gilead Sciences reported sales of The Gilead Sciences EPS (TTM) is 4.78. Gilead Sciences reported sales of 6,667.00, net income of 1,315.00, and EPS of 1.04 for the latest quarter., net income of 1,315.00, and EPS of 1.04 for the latest quarter.

What was Gilead Sciences's net income for the latest quarter?

Gilead Sciences's net income for the latest quarter was 1,315.00.

How did Gilead Sciences's performance compare year-over-year in the latest quarter?

The company's revenue moved from 7,569.00 in the previous quarter to 6,667.00 in the latest quarter, and net income moved from 1,783.00 to 1,315.00 compared to the previous quarter.

What is Gilead Sciences's net profit margin on a TTM basis?

Gilead Sciences's trailing twelve months (TTM) net profit margin is 1.67%.

How does Gilead Sciences's debt to equity ratio compare to industry standards?

Gilead Sciences's total debt-to-equity ratio is 130.79%.

What is Gilead Sciences's return on investment on a TTM basis?

Gilead Sciences's trailing twelve months (TTM) return on investment (ROI) is 32.66%.

Did Gilead Sciences gain or lose cash last quarter?

In the latest quarter, Gilead Sciences's net change in cash was -2,065.00 million.

What were Gilead Sciences's total assets and liabilities in the latest quarter?

As of the latest quarter, Gilead Sciences reported total assets of 56,434.00 million and total liabilities of 12,344.00 million.

How has Gilead Sciences's total revenue grown this year?

Gilead Sciences's total revenue was 7,569.00 in the previous quarter and 6,667.00 in the latest quarter.

What is Gilead Sciences's gross margin on a TTM basis?

Gilead Sciences's trailing twelve months (TTM) gross margin is 78.29%.

What was Gilead Sciences's revenue per share for the latest quarter?

Gilead Sciences's revenue per share for the latest quarter was 37.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.